Intravenous Immunoglobulin Market Overview:
The global intravenous immunoglobulin (IGIV) market was valued at $8,995 million in 2017and is projected to reach $15,964 million by 2025, registering a CAGR of 7.5% from 2018 to 2025.
Immunoglobulins (IGs), also referred to as antibodies, are glycoproteins produced by the blood plasma in response to foreign bodies or antigens. They are highly complex entities and are specific in their action. These immunoglobulins are obtained from blood through the process of fractionation and are purified for use in therapeutic and nontherapeutic areas.
Get a Sample Copy of this Report @ https://www.bigmarketresearch.com/request-sample/2924521?utm_source=hv&utm_medium=sj
Increase in prevalence of immunodeficiency and autoimmune diseases such as chronic inflammatory demyelinating polyneuropathy, hypogammaglobulinemia, & others and rise in adoption of immunoglobulin therapies for the treatment of various autoimmune disorders majorly drive the growth of the IVIG market. Furthermore, increase in approval of IVIG drugs from the Food and Drug Administration (FDA), European Medicine Agency (EMA), and other government agencies is expected to accelerate the growth of the IVIG industry. However, stringent government regulations toward the vigorous use of immunoglobulins, inflated cost of therapy, and high risk of side effects associated with the use of immunoglobulin intravenously are anticipated to hamper the market growth. On the contrary, significant investment in healthcare sector is expected to provide lucrative opportunities for the market growth in the near future.
The global intravenous immunoglobulin (IVIG) market is characterized based on application, type, and region. By application, the market is segmented into hypogammaglobulinemia, CIDP, immunodeficiency diseases, myasthenia gravis, multifocal motor neuropathy, idiopathic thrombocytopenic purpura (ITP), inflammatory myopathies, specific antibody deficiency, Guillain‐Barre syndrome, and others. Depending on type, it is classified into IgG, IgA, IgM, IgE, and IgD. Region wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Key Benefits for Intravenous Immunoglobulin Market:
- The report provides an in-depth analysis of the intravenous immunoglobulin market along with the current trends and future estimations to elucidate the imminent investment pockets.
- A comprehensive analysis of the factors that drive and restrict the market growth is provided in this study.
- The report provides a detailed quantitative analysis of the industry from 2018 to 2025 to assist stakeholders to capitalize on the prevailing market opportunities.
- An extensive analysis of the key segments of the industry helps to understand the trends in the intravenous immunoglobulin market globally.
- Key players and their strategies are provided to understand the competitive outlook of the industry.
Make an inquiry for purchasing this report @ https://www.bigmarketresearch.com/purchase-enquiry/2924521?utm_source=hv&utm_medium=sj
Intravenous Immunoglobulin Key Market Segments:
- Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- Primary Immunodeficiency Disease
- Myasthenia Gravis
- Multifocal Motor Neuropathy
- Idiopathic Thrombocytopenic Purpura (ITP)
- Inflammatory Myopathies
- Specific Antibody Deficiency
- Guillain‐Barre Syndrome
- North America
- Rest of Europe
- Rest of Asia-Pacific
- Saudi Arabia
- Rest of LAMEA
Key Players Profiled
- Baxter international Inc.
- CSL Ltd.
- Grifols, S.A.
- Octapharma AG
- Kedrion Biopharma Inc.
- LFB Group
- Biotest AG
- China Biologics Products, Inc.
- Takeda Pharmaceuticals
- Bayer AG
The other players of the intravenous immunoglobulin market included in the value chain analysis (but not profiled in the report) are as follows:
- Hualan Biological Engineering Inc.
- Omrix Biopharmaceuticals Ltd.
- Behring GmbH
- Shanghai RAAS Blood Products Co., Ltd.
- Option Care Enterprises, Inc.
- ADMA Biologics, Inc.
- BioScrip, Inc.
Get Purchase Discount @ https://www.bigmarketresearch.com/request-for-discount/2924521?utm_source=hv&utm_medium=sj